Title
Category
Credits
Event date
Cost
How Do I…? An Integrated CME Activity Designed to Assess and Compare the Clinical Decisions of Multiple Sclerosis Specialists and General Neurologists (Credit Expired)
$0.00
Program DescriptionMultiple Sclerosis impacts nearly 1 million people in the US and is the leading cause of non-traumatic disability in adults under the age of 50. Accordingly, substantial time and energy has been dedicated to improving understanding of its biological underpinnings and subsequent therapy development. As a result, there are now 18 different disease modifying therapies available representing nine therapeutic classes with several additional options poised to join them.
Module 1: Diagnosis and Progression Monitoring
$0.00
Module 1: Diagnosis and Therapy InitiationThis module focuses on the timely and accurate diagnosis of MS through maximization of the latest technologies and strategies available. It will clarify the changes to the McDonald criteria and address the most common missteps in routine practice that currently pose risks to MS patients. 
Module 2: Initiation and Selection of Disease Modifying Therapy
$0.00
This module will focus on key clinical factors and practical considerations that may impact DMT initiation as well as utilization of the diverse agents available. Factors discussed include age, radiologic versus clinical disease activity, and usefulness of distinguishing between MS categories. It will shed light on how well long-held theories have withstood the test of time and help to provide deeper insight into how experts are approaching the contemporary management of MS.
Module 3: Navigating Controversy: Prognostic Factors, Breakthroughs, and Biomarkers
$0.00
This module will focus on topics of debate in the MS arena including best practices in DMT switching, the impact of race and pregnancy on DMT choice, and the potential role of neurofilament light (NfL) in routine practice. 
From Critique to Consensus: Quantifying & Clarifying Expert Perspectives on the Future Management of Alzheimer's Disease (Credit Expired)
$0.00
Alzheimer's Disease (AD) is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking.
Part 1: Evolving Understanding of Pathophysiology and Modern Proposed Framework of Alzheimer’s Disease
$0.00
Alzheimer's Disease (AD) is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking.
Part 2: Current Treatments and Rising Phase 3 Disease-Modifying Therapies
$0.00
Alzheimer's Disease (AD) is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking.
Part 3: Diagnostic and Therapeutic Monitoring Strategies and their Potential Role in the Future of Disease-Modifying Therapy for Alzheimer’s Disease
$0.00
Alzheimer's Disease (AD) is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking.
Networks in Neurology: New Agents and Strategies for Migraine (Credit Expired)
$0.00
Activity Description One out of six US adults suffer from migraines and yet, until recently, management has been reliant on treatments designed for other conditions that had some consequential success. Fortunately, this long-standing paradigm has not only ended but has accelerated in the opposite direction. The rapid acquisition of new therapies has created a near impossible amount of information to parse out efficiently.
Multiple Sclerosis Management: Shedding Light on the Patient Perspective (Credit Expired)
$0.00
OverviewThis activity, originally held as a satellite symposium in conjunction with the 2021 Consortium of Multiple Sclerosis (MS) Centers (CMSC) Annual Meeting, is designed to contextualize contemporary management approaches through the documented experiences of people with MS. Drs Benjamin Greenberg, Jennifer Graves, and Anthony Traboulsee present data from a large cohort of patients illustrating their perspectives on a variety of management issues related to their care.